Why the study?
Ovarian cancer has a poor prognosis and frequently metastasizes to the omentum, but targeting the microenvironment and reciprocity between cancer cells and omental cells represents an underexplored therapeutic strategy lacking sufficient trials.
Targeting the interaction between ovarian cancer cells and omental adipocytes, potentially through interventions like metformin or exercise, represents a promising therapeutic strategy.
May inform metabolic targeting strategies in ovarian cancer; leaves open prospective trials to confirm clinical efficacy.
Ovarian cancer seriously threatens women’s health because of its poor prognosis and high mortality. Due to the lack of efficient early detection and screening methods, when patients seek doctors’ help with complaints of abdominal distension, back pain and other nonspecific signs, the clinical results always hint at the widespread metastasis of disease. When referring to the metastasis of this disease, the omentum always takes precedence. The distinguishing feature of the omentum is adipose tissue, which satisfies the energy demand of cancer cells and supplies a more aggressive environment for ovarian cancer cells. In this review, we mainly focus on three important cell types: adipocytes, macrophages and mesenchymal stem cells. Besides, several mechanisms underlying cancer-associated adipocytes (CAA)-facilitated ovarian cancer cell development have been revealed, including their capacities for storing lipids and endocrine function, and the release of hormones, growth factors, and adipokines. Blocking the reciprocity among cancer cells and various cells located on the omentum might contribute to ovarian cancer therapy. The inhibition of hormones, growth factors and adipokines produced by adipocytes will be a novel therapeutic strategy. However, a sufficient number of trials has not been performed. In spite of this, the therapeutic potential of metformin and the roles of exercise in ovarian cancer will be worth mentioning. It’s almost impossible to overcome completely ovarian cancer at the moment. What we can do is trying our best to improve these patients’ prognoses. In this process, adipocytes may bring promising future for the therapy of ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: